

# The genomic landscape of small cell lung cancer in never smoking patients

Michael S Oh<sup>1</sup>, Alex Barrett<sup>2</sup>, Arya Ashok<sup>2</sup>, Elizabeth Mauer<sup>2</sup>, Edward B Garon<sup>1</sup>, Aaron E Lisberg<sup>1</sup>, Amy L Cummings<sup>1</sup>, Jonathan W Goldman<sup>1</sup>


<sup>1</sup>Department of Hematology and Oncology, University of California Los Angeles, Los Angeles CA, USA <sup>2</sup>Tempus Labs, Inc, Chicago IL, USA



Smoking status in small cell lung cancer


 SCLC typically found in patients with significant tobacco exposure

- Recent trial data suggest more-thanexpected patients who have never smoked:
  - CASPIAN (Paz-Ares et al, 2019): 6.9%
  - **IMpower133** (Horn et al, 2019): 3.0%






### Molecular analysis in SCLC based on smoking status






# **Demographic composition of SCLC cohort**







# NS patients exhibit unique somatic variant landscape



# Immune microenvironment by smoking status







#### **Conclusions**

- Mutational landscape of SCLC differs based on smoking status
- Tumors of NS more likely to harbor variants in EGFR and PIK3CA
- Potential differences seen in the immune microenvironment
- Future need to explore possible treatment implications



# Thank you!

#### **To Patients and Families**

#### **UCLA Thoracic Oncology**

Edward Garon, Aaron Lisberg, Amy Cummings, Jonathan Goldman

#### **Tempus Team**

Alex Barrett, Arya Ashok, Elizabeth Mauer, Amrita A. Iyer



